SBCSBC Medical Group Holdings Incorporated
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−5% a year). The price bakes in little to no growth.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SBC's price assumes
SBC Medical Group Holdings Incorporated trades at 11.3× earnings against 18.0× for the median Consulting Services name, cheaper than its own group.
Trailing P/E · Consulting Services median 18.0 · cheaper than the typical name in its group
- Price / sales
- 2.54
Price / sales · as of 2026-Q1
- Free cash flow yield
- 11%
Free cash flow yield · Consulting Services median 8.5%
- Growth the price implies
- −5.3%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / bookas of 2026-Q1
- 1.68
- EV / EBITas of 2026-Q1
- 5.16
- EV / salesas of 2026-Q1
- 1.86
- Industrials median P/E440 names
- 26.5
- Consulting Services median P/E10 names
- 18.0
- Free cash flow, trailing twelve months
- $62M
- Market capitalisation
- $548M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Consulting Services
The closest names by size in the same industry